Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFMG |
Texto Completo: | https://doi.org/10.7717/peerj.12124 http://hdl.handle.net/1843/61926 https://orcid.org/0000-0002-8876-4907 https://orcid.org/0000-0001-7656-1849 https://orcid.org/0000-0002-0560-8491 |
Resumo: | Breast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done. |
id |
UFMG_72d345385d0aee9173140601dddc0a4c |
---|---|
oai_identifier_str |
oai:repositorio.ufmg.br:1843/61926 |
network_acronym_str |
UFMG |
network_name_str |
Repositório Institucional da UFMG |
repository_id_str |
|
spelling |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cellsTamoxifen citrateNanofibersPolycaprolactoneBreast CancerBioquímicaBioengenhariaBiotecnologia farmacêuticaMamas - CâncerCâncer - TratamentoReceptores hormonaisTecnologia de liberação controladaBreast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorUniversidade Federal de Minas GeraisBrasilFAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORAICX - DEPARTAMENTO DE QUÍMICAUFMG2023-12-12T18:45:53Z2023-12-12T18:45:53Z2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlepdfapplication/pdfhttps://doi.org/10.7717/peerj.121242167-8359http://hdl.handle.net/1843/61926https://orcid.org/0000-0002-8876-4907https://orcid.org/0000-0001-7656-1849https://orcid.org/0000-0002-0560-8491engPeerJAna Delia Pinzón GarcíaRubén Dario Sinisterra MillánMaría Esperanza Cortés SeguraFredy MesaSandra Ramírez-Clavijoinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2023-12-12T18:45:55Zoai:repositorio.ufmg.br:1843/61926Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-12-12T18:45:55Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
dc.title.none.fl_str_mv |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
title |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
spellingShingle |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells Ana Delia Pinzón García Tamoxifen citrate Nanofibers Polycaprolactone Breast Cancer Bioquímica Bioengenharia Biotecnologia farmacêutica Mamas - Câncer Câncer - Tratamento Receptores hormonais Tecnologia de liberação controlada |
title_short |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
title_full |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
title_fullStr |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
title_full_unstemmed |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
title_sort |
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
author |
Ana Delia Pinzón García |
author_facet |
Ana Delia Pinzón García Rubén Dario Sinisterra Millán María Esperanza Cortés Segura Fredy Mesa Sandra Ramírez-Clavijo |
author_role |
author |
author2 |
Rubén Dario Sinisterra Millán María Esperanza Cortés Segura Fredy Mesa Sandra Ramírez-Clavijo |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Ana Delia Pinzón García Rubén Dario Sinisterra Millán María Esperanza Cortés Segura Fredy Mesa Sandra Ramírez-Clavijo |
dc.subject.por.fl_str_mv |
Tamoxifen citrate Nanofibers Polycaprolactone Breast Cancer Bioquímica Bioengenharia Biotecnologia farmacêutica Mamas - Câncer Câncer - Tratamento Receptores hormonais Tecnologia de liberação controlada |
topic |
Tamoxifen citrate Nanofibers Polycaprolactone Breast Cancer Bioquímica Bioengenharia Biotecnologia farmacêutica Mamas - Câncer Câncer - Tratamento Receptores hormonais Tecnologia de liberação controlada |
description |
Breast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 2023-12-12T18:45:53Z 2023-12-12T18:45:53Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.7717/peerj.12124 2167-8359 http://hdl.handle.net/1843/61926 https://orcid.org/0000-0002-8876-4907 https://orcid.org/0000-0001-7656-1849 https://orcid.org/0000-0002-0560-8491 |
url |
https://doi.org/10.7717/peerj.12124 http://hdl.handle.net/1843/61926 https://orcid.org/0000-0002-8876-4907 https://orcid.org/0000-0001-7656-1849 https://orcid.org/0000-0002-0560-8491 |
identifier_str_mv |
2167-8359 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
PeerJ |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
pdf application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil FAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORA ICX - DEPARTAMENTO DE QUÍMICA UFMG |
publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais Brasil FAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORA ICX - DEPARTAMENTO DE QUÍMICA UFMG |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
instname_str |
Universidade Federal de Minas Gerais (UFMG) |
instacron_str |
UFMG |
institution |
UFMG |
reponame_str |
Repositório Institucional da UFMG |
collection |
Repositório Institucional da UFMG |
repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
repository.mail.fl_str_mv |
repositorio@ufmg.br |
_version_ |
1816829769777414144 |